Shinde A, et al. - Researchers used the National Cancer Database to assess the influence of adjuvant chemotherapy (CT) and/or radiation (RT) in patients with non-metastatic, clinically N2 non-small cell lung cancer who underwent neoadjuvant chemotherapy followed by surgical resection. Overall 1,541 patients were selected. In the overall cohort, adjuvant CT or RT offered no benefit. Improved survival was observed in relation to receiving adjuvant CT and RT in patients with persistent N2 disease and lymph node ratio > 15%. Patients with ypN0-1 or lymph node ratio < 15% do not see a benefit with adjuvant therapy, while patients with ypN2 and lymph node ratio > 15% do. In other words, patients with persistent or high nodal burden disease seemed to be benefitted, in terms of survival, with the use of aggressive consolidative therapy.